SHIRLEY, NY, October 27, 2026 -- Creative Biolabs, a global leader in biotechnology and contract research services, today announced the launch of its integrated OMV & exosome-boosted CAR-T development platform, a next-generation vesicle-engineering approach designed to investigate strategies addressing barriers to CAR-T activity in solid-tumor models.
The Solid Tumor Challenge in CAR-T Immunotherapy
While CAR-T therapy has transformed outcomes in hematological malignancies, its impact on solid tumors remains constrained by three fundamental obstacles: poor T-cell infiltration through dense tumor stroma, an immunosuppressive tumor microenvironment (TME) that drives metabolic exhaustion, and safety concerns such as cytokine release syndrome (CRS), together with antigen heterogeneity and escape. Conventional CAR-T approaches alone have struggled to surmount these barriers simultaneously.
Dual-Vesicle CAR-T Engineering: OMV and Exosome Strategies for Solid Tumor Penetration
Creative Biolabs' new platform integrates two complementary nanoscale vesicle technologies—bacterial outer membrane vesicles (OMVs) and mammalian-derived exosomes—into a unified, customizable pipeline for vesicle-enabled CAR-T research and tumor-microenvironment modulation. Each vesicle type addresses a distinct bottleneck, enabling researchers to evaluate complementary effects across multiple barriers.
"For years, the field has accepted that solid tumors require a fundamentally different approach to CAR-T therapy," said a senior scientist at Creative Biolabs. "By integrating OMV and exosome engineering into a single platform, we're giving researchers a dual-mechanism toolkit that doesn't just chip away at these barriers—it enables researchers to investigate them in parallel, from stroma penetration to metabolic persistence."
OMV Engineering: Remodeling the Tumor Stroma
The platform's OMV engineering arm functionally remodels the tumor microenvironment to promote CAR-T infiltration. Engineered OMVs can carry selected immunomodulatory or delivery payloads for investigating tumor-microenvironment remodeling and CAR-T infiltration. A standout innovation is the BROAD-CAR system, in which OMVs transiently program tumor cells in vivo to display synthetic antigens recognized by a universal CAR-T construct—providing a preclinical strategy for evaluating antigen redirection across heterogeneous tumor models.
Additionally, OMV surface engineering with targeting ligands guides CAR-T homing precision, while detoxified LPS strains require characterization of immunostimulatory activity and endotoxin-related safety — a critical differentiator from synthetic liposome carriers that lack intrinsic immune-activating capacity.
Mammalian Exosome Engineering: Sustaining CAR-T Persistence
The exosome engineering arm provides a biocompatible support system to sustain CAR-T activity within the suppressive TME. CAR-exosomes—exosomes directly displaying functional CARs on their surface—deliver antigen-specific tumor killing without live cell administration, with a safety profile that requires preclinical comparison with live-cell CAR-T approaches. Selected exosome systems are being investigated for transport across biological barriers, including the blood-brain barrier and can be engineered to carry cytokines, checkpoint inhibitors, and survival signals that are intended to modulate CAR-T exhaustion and persistence.
Cargo Loading & Formulation: Metabolic Armoring
A third service line equips both vesicle types with customized therapeutic payloads. Small molecules, nucleic acids (mRNA, siRNA, miRNA), and proteins can be co-encapsulated within a single vesicle for multimodal synergy. Metabolic TME remodeling formulations alleviate iron-mediated oxidative stress, while vesicle-mediated checkpoint blockade enables localized, sustained PD-1/PD-L1 inhibition directly at tumor sites—maximizing activation while minimizing systemic toxicity.
What Researchers Should Evaluate in Vesicle-Boosted CAR-T Platforms
When selecting a vesicle-engineering partner for CAR-T potentiation, research teams should assess three practical criteria:
- Dual-modality integration: Confirm the platform supports both OMV and exosome engineering. Single-vesicle approaches address only one barrier at a time — dual integration is critical for simultaneous stroma remodeling and persistence support.
- LPS detoxification data: Verify that detoxified LPS strains are used and endotoxin-level data is available. Untreated OMVs carry significant endotoxin risk that can confound preclinical safety models.
- Cargo co-loading capacity: Ensure the platform can package small molecules, nucleic acids, and proteins within a single vesicle. This co-delivery capability is essential for combination strategies targeting multiple TME pathways simultaneously.
Platform Differentiators
- Antigen-independent targeting via synthetic marker installation on cancer cells
- Payload capacity and immunogenicity characterized relative to selected synthetic carriers
- Cell-free CAR-exosome options for preclinical repeat-dosing and formulation studies
- Project-specific ex vivo workflows designed to preserve favorable T-cell phenotypes
- Full technical validation including NTA sizing, high-resolution imaging, and pharmacokinetic profiling
Ready to break through the solid tumor barrier? Visit https://www.creative-biolabs.com/car-t/ to download the full technical brief on OMV-exosome CAR-T engineering, or contact our scientific team to discuss your specific tumor model and therapeutic targets today.
About Creative Biolabs
Creative Biolabs is a biotechnology company pioneering OMV and exosome-engineered CAR-T solutions, offering integrated vesicle development services—from stroma remodeling and cell-free immunotherapy to cargo-loaded potentiation—for researchers advancing solid tumor therapies.